Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Decision Resources Group
Next-Generation Products Will Expand the Treatable Patient Population and Drive Growth, According to Decision Resources Group
TORONTO, Jan. 21, 2014 /PRNewswire/ -- According to Decision Resources Group, the United States and European peripheral vascular (PV) device markets will continue to grow through 2022 as the prevalence and diagnosis of peripheral vascular disease expands. Furthermore, the market will be driven by the introduction of next-generation devices, including abdominal aortic stent grafts, drug-coated balloons (DCBs) and flexible femoropopliteal (fem-pop) self-expandable (SX) stents.
In the abdominal aortic stent graft space, manufacturers have made significant strides in expanding the treatable patient population. Although original devices could only be used in a small number of specific cases, new technologies have been developed that can treat more complicated cases such as short-neck, no-neck and angulated-neck aneurysms. Companies are also developing off-the-shelf fenestrated grafts as an alternative to expensive customized devices for patients with aneurysms close to the renal and visceral arteries. Notably, smaller companies such as Endologix, TriVascular and Lombard Medical Technologies have been actively working on product development in this space, and may be able to disrupt the strong hold that Medtronic, Cook Medical and W. L. Gore have on the market.
"DCBs represent another important product development, and although they've been a hot topic for awhile, we're really starting to see their effect on the market now," said DRG Analyst Tonya Martin. "In Europe, unit sales will grow at an average of 26 percent per year through 2022 as countries begin to establish reimbursement policies. Approval of DCBs in the US is anticipated in late 2014, and physicians are anxious to catch up with their European colleagues. However, drug-eluting stents (DES) are showing particularly strong potential in the US, which will hurt adoption of DCBs. Furthermore, many upcoming products in the flexible fem-pop SX stent space from Boston Scientific, Covidien, W. L. Gore, Abbott and Cordis will compete with both DCBs and DES."
Overall, the premium price of new products combined with a greater potential patient pool will drive moderate growth in the US and European PV device markets, despite pricing pressures.
Decision Resources Group's US Markets for Peripheral Vascular Devices 2014 and European Markets for Peripheral Vascular Devices 2014 reports include unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for PV stents, percutaneous transluminal angioplasty balloon catheters, atherectomy devices, chronic total occlusion crossing devices, embolic protection devices, aortic stent grafts, synthetic surgical grafts and PV accessory devices in the United States, France, Germany, Italy, Spain and the United Kingdom.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
©2012 PR Newswire. All Rights Reserved.